http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36775189

Outgoing Links

Predicate Object
contentType Journal Article
issn 2766-5526
issueIdentifier 2
pageRange EVIDoa2100044-
publicationName NEJM Evidence
startingPage EVIDoa2100044
bibliographicCitation Caraco Y, Crofoot GE, Moncada PA, Galustyan AN, Musungaie DB, Payne B, Kovalchuk E, Gonzalez A, Brown ML, Williams-Diaz A, Gao W, Strizki JM, Grobler J, Du J, Assaid CA, Paschke A, Butterton JR, Johnson MG, De Anda C. Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults. NEJM Evid. 2022 Feb;1(2):EVIDoa2100043. doi: 10.1056/evidoa2100043. PMID: 38319179.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_78be9f0e17b37ebacae2d4c68d4cfb28
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ffe329ae152d38959aca509601218fba
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4b29ba6f4c139e7f358bef35e500210e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d2ad6ee0bcfbc6893bbdb61ef6f46bce
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_136588e060a4a7f45d7e5b2e9bf009a0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_330fab56fcd859dce5e53c2ff97a6406
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b77f78f169054788e5da233cb3d4d4d5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_54b70f2bec36bad70a8facc8f4988c1d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-7223-7611
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6a9600af2042618b92b23b13caa43dab
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eab52a2bb960db5cb970c7e236a3059e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9a610d310880aa317257cb2fc6bc2708
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d7422d7315a4017be0c63de2e1cdb561
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_69b341945a0dc97f45ea22c0a259b3f5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ef50c99729ac770cab2815459a135b2d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_14b483bc78492ea41af621ab57bb66f2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f401fd46a6fca0135f4101050f52470f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1362683ac2c28e7e60381464c68f97e4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e802115351081dc78c9ae8ebb6dfc52a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_edfb65289949c59f7158278dae11e994
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb530bad5ad88764ee0c10914aa739ce
date 2022-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/38319179
https://pubmed.ncbi.nlm.nih.gov/38319178
https://doi.org/10.1056/evidoa2100044
https://doi.org/10.1056/evidoa2100043
isPartOf https://portal.issn.org/resource/ISSN/2766-5526
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/51507
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults

Total number of triples: 39.